GQG Partners LLC Has $1.12 Billion Stock Position in Novo Nordisk A/S (NYSE:NVO)

GQG Partners LLC grew its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 74.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,994,533 shares of the company's stock after acquiring an additional 5,556,460 shares during the quarter. Novo Nordisk A/S accounts for 1.7% of GQG Partners LLC's portfolio, making the stock its 22nd largest holding. GQG Partners LLC owned approximately 0.29% of Novo Nordisk A/S worth $1,117,790,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Daiwa Securities Group Inc. bought a new position in shares of Novo Nordisk A/S during the 3rd quarter worth about $28,000. Center for Financial Planning Inc. raised its holdings in Novo Nordisk A/S by 72.4% in the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after acquiring an additional 123 shares in the last quarter. Dunhill Financial LLC lifted its position in shares of Novo Nordisk A/S by 196.8% in the 3rd quarter. Dunhill Financial LLC now owns 469 shares of the company's stock worth $56,000 after acquiring an additional 311 shares during the period. Albion Financial Group UT grew its holdings in shares of Novo Nordisk A/S by 121.4% during the 4th quarter. Albion Financial Group UT now owns 507 shares of the company's stock worth $44,000 after purchasing an additional 278 shares in the last quarter. Finally, Hager Investment Management Services LLC bought a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $46,000. Institutional investors and hedge funds own 11.54% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

NVO has been the subject of several research reports. BNP Paribas raised Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, December 2nd. UBS Group raised shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a report on Wednesday, January 8th. Stifel Nicolaus cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a research note on Wednesday, February 12th. They set an "equal weight" rating for the company. Finally, Kepler Capital Markets upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $145.25.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO traded down $0.81 during trading on Friday, reaching $69.36. The stock had a trading volume of 5,852,065 shares, compared to its average volume of 5,563,763. The stock has a market capitalization of $311.23 billion, a PE ratio of 21.08, a P/E/G ratio of 0.90 and a beta of 0.42. Novo Nordisk A/S has a 52 week low of $69.18 and a 52 week high of $148.15. The business's 50-day moving average price is $82.33 and its 200 day moving average price is $99.11. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, equities analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be given a $0.7874 dividend. This represents a yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. This is a boost from Novo Nordisk A/S's previous semi-annual dividend of $0.51. Novo Nordisk A/S's dividend payout ratio (DPR) is presently 47.72%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.